Tenofovir disoproxil fumarate (TDF) plus ritonavir-boosted protease inhibitor (PI) regimens appear to be associated with greater renal function decline

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1188, 2008-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tenofovir disoproxil fumarate (TDF) plus ritonavir-boosted protease inhibitor (PI) regimens appear to be associated with greater renal function decline

By  

Inpharma, Vol. 1, Iss. 1624, 2008-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Tipranavir: A Ritonavir-Boosted Protease Inhibitor

By Croom Katherine F.   Keam Susan J.  

Drugs, Vol. 65, Iss. 12, 2005-01 ,pp. : 1669-1677

Adis International

Access to resources Recommend Favorite

Emtricitabine/Tenofovir Disoproxil Fumarate: In Combination with a Protease Inhibitor in HIV-1 Infection

By Perry Caroline M.  

Drugs, Vol. 69, Iss. 7, 2009-05 ,pp. : 843-857

Adis International

Access to resources Recommend Favorite

Tipranavir: A Ritonavir-Boosted Protease Inhibitor: A Viewpoint by Charles Hicks

By Hicks Charles  

Drugs, Vol. 65, Iss. 12, 2005-01 ,pp. : 1678-1679

Adis International

Access to resources Recommend Favorite

Antiretrovirals: Histoplasmosis (first report with lopinavir, ritonavir and tenofovir disoproxil fumarate) associated with immune reconstitution syndrome: 3 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1086, 2006-01 ,pp. : 6-7

Adis International

Access to resources Recommend Favorite